← Home / ADIAL PHARMACEUTICALS, INC. (ADIL)
Stock Analysis
ADIAL PHARMACEUTICALS, INC. (ADIL)
ADIL
ADIL · Market data
3.34 +1.52%
Track ADIL in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when ADIL price is:
52W Range Position
20%
LOWMIDHIGH
Trend
Mixed
Momentum
Neutral
Updated: 2026-08-02 14:43 UTC
WOI Investment Thesis
Mixed
Confirmation improves above 4.15. Holding above 2.65 keeps the current thesis intact.
⚖️
✓
Fundamentals
Insufficient / Insufficient
✓
Price Structure
Mixed
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
2.65
↗
Break Above
Confirmation improves above resistance.
4.15
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 2.65
Recent Company Events
SEC VERIFIED
Latest material filings
JUN
11
◆
M&A
HIGH
ADIL merger or acquisition update
Shares of Common Stock held by the holders thereof immediately prior to the First Effective Time remain outstanding and unaffected by the Merger.
8-K Filing • SEC EDGAR
MAY
11
●
Financial Results
HIGH
Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
Glen Allen, VA – May 11, 2026 – Adial Pharmaceuticals, Inc.
8-K Filing • SEC EDGAR
What's Driving ADIL?
📈 Technical recovery is improving
Momentum is Neutral. Watch 4.15 for confirmation and 2.65 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 2.65 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
73.2
◎
How to read this setup
From a roadmap perspective, the setup is boxed by support near 2.65 and resistance around 4.67. Clearing resistance would strengthen the constructive case, while a failure through support would damage the present setup.
Price Chart
ADIL — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$5.0M
Company size
EV
$691,399
Debt-adjusted value
P/E
-0.6
Not meaningful
P/B
1.4
Low book multiple
EV/EBIT
-0.1
Not meaningful
P/FCF
-0.8
Not meaningful
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
↗
Revenue Growth
Insufficient
●
Profitability
Insufficient
≈
Cash Flow
Recovering
⚖
Balance Sheet
Strong
📈 Net Income
-2.02M
≈ Insufficient
🧮 EPS (Basic)
-1.48
≈ Insufficient
ADIAL PHARMACEUTICALS, INC.
Related Opportunities